Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
16.79
Dollar change
+0.88
Percentage change
5.53
%
IndexRUT P/E- EPS (ttm)-1.89 Insider Own23.13% Shs Outstand256.14M Perf Week6.47%
Market Cap4.69B Forward P/E- EPS next Y-0.84 Insider Trans18.95% Shs Float214.70M Perf Month117.21%
Income-444.04M PEG- EPS next Q-0.42 Inst Own64.84% Short Float20.02% Perf Quarter195.60%
Sales1.19M P/S3940.85 EPS this Y28.90% Inst Trans-2.02% Short Ratio4.13 Perf Half Y172.56%
Book/sh2.28 P/B7.36 EPS next Y37.24% ROA-61.49% Short Interest42.98M Perf Year130.00%
Cash/sh1.00 P/C16.76 EPS next 5Y- ROE-81.91% 52W Range3.21 - 18.33 Perf YTD106.52%
Dividend Est.- P/FCF- EPS past 5Y-8.25% ROI-68.03% 52W High-8.40% Beta0.62
Dividend TTM- Quick Ratio2.70 Sales past 5Y0.00% Gross Margin-3091.17% 52W Low423.05% ATR (14)1.32
Dividend Ex-Date- Current Ratio2.79 EPS Y/Y TTM23.77% Oper. Margin-38734.99% RSI (14)73.19 Volatility8.91% 9.87%
Employees557 Debt/Eq0.13 Sales Y/Y TTM- Profit Margin-37345.42% Recom1.29 Target Price25.17
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q28.86% Payout- Rel Volume1.06 Prev Close15.91
Sales Surprise-66.55% EPS Surprise-4.46% Sales Q/Q- EarningsFeb 28 AMC Avg Volume10.42M Price16.79
SMA2044.39% SMA5075.34% SMA200137.57% Trades Volume10,992,444 Change5.53%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Initiated Goldman Buy $12
Sep-18-23Reiterated Barclays Overweight $40 → $18
May-30-23Upgrade Wells Fargo Equal Weight → Overweight $11 → $17
Mar-27-23Resumed Wells Fargo Equal Weight $11
Jan-27-23Upgrade Piper Sandler Neutral → Overweight $11 → $14
Dec-09-22Downgrade Goldman Buy → Neutral $20 → $6
Oct-31-22Initiated Guggenheim Neutral
Aug-18-22Resumed Wells Fargo Equal Weight $14
Jan-28-22Upgrade Stifel Hold → Buy $23 → $25
Dec-07-21Resumed Cowen Outperform
Mar-02-24 06:50AM
Mar-01-24 05:00PM
Feb-29-24 05:47PM
12:17PM
10:37AM
09:44AM Loading…
09:44AM
05:51AM
Feb-28-24 05:35PM
04:42PM
04:35PM
04:01PM
Feb-27-24 08:52AM
Feb-26-24 05:39AM
Feb-25-24 08:07AM
05:01AM
06:14AM Loading…
Feb-23-24 06:14AM
Feb-22-24 08:45AM
04:00AM
Feb-20-24 03:38PM
11:02AM
08:00AM
06:30AM
Feb-19-24 08:36AM
Feb-16-24 05:30PM
04:04PM
03:38PM
03:35PM
03:19PM
Feb-12-24 07:14AM
Feb-08-24 07:27AM
05:10AM Loading…
Feb-07-24 05:10AM
Feb-05-24 05:25AM
Feb-04-24 06:27AM
Jan-19-24 05:15PM
Jan-15-24 12:27PM
Jan-08-24 05:31AM
Dec-28-23 05:59PM
11:13AM
08:01AM
Dec-27-23 05:26PM
02:02PM
12:21PM
12:21PM
11:21AM
10:41AM
09:57AM
07:06AM
07:00AM
Dec-22-23 05:15PM
Dec-18-23 02:58PM
Dec-12-23 08:45AM
05:29AM
Dec-07-23 11:31AM
Nov-20-23 12:00PM
Nov-17-23 05:00PM
Nov-08-23 05:04PM
01:03PM
07:55AM
Nov-07-23 04:26PM
04:01PM
Oct-31-23 04:01PM
09:05AM
Oct-24-23 06:54AM
Oct-20-23 05:15PM
Oct-16-23 08:15AM
Sep-27-23 04:01PM
Sep-22-23 06:25PM
Sep-15-23 04:20PM
07:26AM
Sep-14-23 06:10PM
04:36PM
Sep-07-23 11:30AM
07:31AM
Aug-31-23 10:16PM
Aug-28-23 11:53PM
Aug-18-23 05:00PM
Aug-09-23 11:14AM
Aug-08-23 05:50PM
04:50PM
04:01PM
Jul-31-23 06:10AM
Jul-25-23 04:01PM
Jul-24-23 04:01PM
Jul-21-23 05:34PM
Jul-13-23 04:01PM
Jul-11-23 04:30PM
11:18AM
10:53AM
09:26AM
04:56AM
Jul-10-23 09:46PM
04:34PM
07:00AM
Jun-24-23 03:19PM
Jun-20-23 07:01AM
Jun-16-23 08:39AM
Jun-15-23 07:01AM
Jun-09-23 07:01AM
Jun-08-23 11:30AM
May-30-23 04:18PM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rothbaum Wayne P.DirectorFeb 20Buy9.155,000,00045,750,00028,067,333Feb 20 04:11 PM
MCPEAK MERRILL ADirectorFeb 20Buy9.15250,0002,287,500320,150Feb 20 07:52 PM
Dukes Iain D.DirectorFeb 20Buy9.1532,000292,80054,000Feb 20 04:21 PM
Vogt Frederick GInterim CEO & General CounselJan 16Option Exercise0.0020,8340105,668Jan 18 06:09 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJan 16Option Exercise0.002,813035,184Jan 18 06:09 PM
BILINSKY IGORChief Operating OfficerJan 16Option Exercise0.002,813031,444Jan 18 06:07 PM
Vogt Frederick GInterim CEO & General CounselOct 16Option Exercise0.0020,835093,685Oct 18 08:05 PM
BILINSKY IGORChief Operating OfficerOct 16Option Exercise0.002,813030,026Oct 18 08:04 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerOct 16Option Exercise0.002,813033,766Oct 18 08:03 PM
MCPEAK MERRILL ADirectorSep 18Buy5.5610,00055,600248,633Sep 19 04:30 PM
Rothbaum Wayne P.DirectorSep 15Buy5.305,000,00026,500,00023,067,333Sep 15 06:12 PM
BILINSKY IGORChief Operating OfficerJul 14Option Exercise0.002,813028,608Jul 17 06:21 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJul 14Option Exercise0.002,813032,348Jul 17 06:22 PM
Vogt Frederick GInterim CEO & General CounselJul 14Option Exercise0.0020,834081,701Jul 17 06:22 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerApr 14Option Exercise0.002,812030,930Apr 18 05:49 PM
Vogt Frederick GInterim CEO & General CounselApr 14Option Exercise0.0020,834069,718Apr 18 05:50 PM
BILINSKY IGORChief Operating OfficerApr 14Option Exercise0.002,812027,190Apr 18 05:48 PM